{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG|Designated|Treatment of Amyotrophic lateral sclerosis" in comments (approximate match)
Status:
US Approved Rx
(2023)
Source:
NDA217171
(2023)
Source URL:
First approved in 2021
Source:
NDA215014
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1992)
Source:
BLA103293
(1992)
Source URL:
First approved in 1992
Source:
BLA103293
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2018)
Source:
BLA761080
(2018)
Source URL:
First approved in 1991
Source:
BLA103353
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04322149: Phase 2 Interventional Completed Amyotrophic Lateral Sclerosis
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03508453: Phase 2 Interventional Withdrawn Amyotrophic Lateral Sclerosis
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00351767: Phase 2 Interventional Completed Foot Ulcer, Diabetic
(2006)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04577300: Phase 2 Interventional Recruiting Glaucoma
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04129775: Phase 1/Phase 2 Interventional Completed Sensorineural Hearing Loss
(2019)
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:906122
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:725319
Source URL:
Class:
PROTEIN
